Pelthos Therapeutics Inc.
SEC CIK 1919246 · PTHS · last insider filing 2026-06-17
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Friedberg Ezra M | Director | filed 2024 - 2026 |
| Davis Todd C | Director | filed 2024 - 2026 |
| Greenleaf Peter | Director | filed 2025 - 2026 |
| Pauls Matthew | Director | filed 2025 - 2026 |
| Malamut Richard | Director | filed 2024 - 2026 |
| Plesha Scott M. | Director · CEO and President | filed 2025 - 2026 |
| Baxter Richard B | Director | filed 2025 - 2026 |
| Einhorn Andrew J. | Director | filed 2025 - 2025 |
| Ligand Pharmaceuticals INC | Director | filed 2025 - 2025 |
| Simmons Chia-Lin | Director | filed 2024 - 2025 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Francis Knuettel II | Interim CEO, CFO, Treas & Sec | filed 2024 - 2026 |
| GAY John M. | Chief Financial Officer | filed 2026 - 2026 |
| Rangarao Sai | Chief Commercial Officer | filed 2025 - 2026 |
| Lang Eric | Chief Medical Officer | filed 2024 - 2024 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.